INCYTE CORP Form 8-K November 02, 2010

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 2, 2010

INCYTE CORPORATION

(Exact name of registrant as specified in its charter)

Delaware 0-27488 94-3136539

(State or Other Jurisdiction of Incorporation)

(Commission File Number)

(I.R.S. Employer Identification No.)

Experimental Station
Route 141 & Henry Clay Road
Building E336
Wilmington, DE
(Address of principal executive offices)

19880 (Zip Code)

(302) 498-6700

(Registrant s telephone number, including area code)

N/A

(Former name or former address, if changed since last report.)

Item 8.01 Other Events.

On November 2, 2010, Incyte Corporation (the Company) issued a press release announcing the achievement of milestones pursuant to the Collaboration and License Agreement, dated November 24, 2009, by and between the Company and Novartis International Pharmaceutical Ltd. A copy of the press release dated November 2, 2010 is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.

- (d) Exhibits
- 99.1 Press release issued by Incyte Corporation dated November 2, 2010.

2

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: November 2, 2010

INCYTE CORPORATION

By:

/s/ Patricia A. Schreck
Patricia A. Schreck
Executive Vice President and
General Counsel

3